SLS
NasdaqCMSELLAS Life Sciences Group, Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 10 recent filings. None are open-market buys/sells — recent activity is grants, option exercises, gifts or tax withholding (which don't signal conviction).
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
Stergiou Angelos M. Director, President and CEO | Grant / award | 1.07M | $0.00 | — | 2026-06-16 |
Varian John Director | Grant / award | 50K | $0.00 | — | 2026-01-07 |
VAN NOSTRAND ROBERT L Director | Grant / award | 50K | $0.00 | — | 2026-01-07 |
SCHEINBERG DAVID A Director | Grant / award | 50K | $0.00 | — | 2026-01-07 |
CICIC DRAGAN SVP, Chief Development Officer | Grant / award | 300K | $0.00 | — | 2026-01-07 |
Burns John Thomas CFO | Grant / award | 300K | $0.00 | — | 2026-01-07 |
Kalin Katherine Bach Director | Grant / award | 50K | $0.00 | — | 2026-01-07 |
Wasman Jane Director | Grant / award | 50K | $0.00 | — | 2026-01-07 |
CICIC DRAGAN SVP, Chief Development Officer | Code J | 63.8K | $1.50 | $95,700.00 | 2025-12-03 |
Burns John Thomas CFO | Code J | 58.59K | $1.50 | $87,888.00 | 2025-12-03 |
Source: SEC EDGAR Forms 4/4A (CIK 1390478). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
$SLS they wanted your shares cheap! Be vigilant 💪
$SLS New week . Here is to a green week fam bam 😃💥💥
$SLS
$SLS 80th Event PR and Topline Phase 3 Results and Ensuing Share Price Launch • NOW Imminent. SLS is worth $100+ per share the Instant the Gps Phase 3 Results are announced - Registrational results Giving Gps the FDA greenlight to generate tens of billions of dollars in real revenue each year.
$SLS All These From My Front Yard ! Is This The Week ? 🙏🎉🙏
$SLS another one of my friends died of cancer today...I have another with AML. This is getting really tough that people can not get this treatment yet. I dont wish death on anyone. I just want this trial to be with so people can get access to the treatment sooner.
$SLS
$SLS not one for long articles since they got us hooked on short-form everything but this article is interesting, shares a new perspective (for me) and is packed with information. I am interested in small cap biotechs especially ones that disrupt medical outcomes we have been conditioned to accept as inevitable. Thanks Rob.
$SLS $ABBV $BMY $XBI AZA + Ven, BAT for the SLS Phase control arm, recently failed 3 large Phase 3 trials conducted by Abbv. Including failing the Viale-M Phase 3 Trial for Aml first remission maintenance. Aza Ven failed the sls p3 second remission control arm patients too.
$SLS With AstraZeneca and Bristol Myers Squibb in massive merger talks and Johnson & Johnson throwing billions around to hit their 2030 oncology goals, Merck cannot afford to let a rival capture a turnkey, National Cancer Institute #1 ranked platform. This environment turns the Phase 3 REGAL trial readout into an absolute prize. Merck will be forced to bid aggressively just to survive.
$SLS 🔥🔥🔥
$SLS
Latest news
SLS Stock Hits 1-Month Low On China Arbitration Blow — Retail Bulls Call It A ‘Nothingburger’ Ahead Of AML Readout
SLS Stock Climbs Premarket: Here’s What Smart Money Is Doing As Sellas Nears Critical Phase 3 AML Readout
Sellas CEO Angelos Stergiou Says ‘100% Certain’ AI Can Be Used To Beat Cancer
SLS Stock Rises Overnight: Retail Traders Call New AML Survival Data 'Huge' Ahead Of CEO’s Fox Appearance
SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas
SLS Stock Tracks Worst Month Since March: Investor Slashes Stake By Over 30% As Quiet Period Begins Ahead Of AML Readout
SLS Stock Rises Overnight: Retail Thinks CEO Just Dropped Buyout Clues Ahead Of Fox Appearance
SLS Stock Jumps Ahead Of CEO’s Fox Appearance: Retail Bets AML Readout Could Spark Big Pharma Bidding War
Will Near-Complete REGAL Phase 3 GPS Data and New Executive Terms Change SELLAS Life Sciences Group's (SLS) Narrative
SELLAS Life Sciences Group (SLS) Stock Looks Rich On Book Value Yet Strong On Returns
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.